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The T-cell Response to Epstein-Barr
Virus–New Tricks From an Old Dog
Heather M. Long*, Benjamin J. Meckiff and Graham S. Taylor*
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
Epstein-Barr virus (EBV) infects most people and establishes life-long infection controlled
by the host’s immune system. The genetic stability of the virus, deep understanding of
the viral antigens and immune epitopes recognized by the host’s T-cell system and the
fact that recent infection can be identified by the development of symptomatic infectious
mononucleosis makes EBV a powerful system in which to study human immunology. The
association between EBV and multiple cancers also means that the lessons learned have
strong translational potential. Increasing evidence of a role for resident memory T-cells
and non-conventional γδ T-cells in controlling EBV infection suggests new opportunities
for research andmeans the virus will continue to provide exciting new insights into human
biology and immunology into the future.
Keywords: resident memory, nasopharyngeal carcinoma (NPC), tumor virus, DLBCL - Diffuse large B cell
lymphoma, Burkitt lymphoma, gamma delta T cells, cytotoxic CD4 T cell, Hodgkin Lymphoma
INTRODUCTION
Epstein-Barr virus (EBV) was first identified in 1964 in a biopsy from a patient with Burkitt
Lymphoma (1). This gammaherpesvirus has co-evolved with humans for millennia and is a highly
successful pathogen, infecting 90–95% of people worldwide who then carry the virus for life. EBV
infection normally occurs in young children with few if any symptoms (2). However, if acquisition
is delayed to adolescence then 25–75% of those infected develop infectious mononucleosis (IM).
This is an acute syndrome characterized by a tetrad of symptoms: fever, fatigue, sore throat, and
lymphadenopathy (3, 4). The acute symptoms of IM usually resolve by themselves, but serious rare
complications may occur which include airway obstruction and splenic rupture (2). Longer term,
a history of IM is associated with a raised incidence of Hodgkin lymphoma (HL) in the decade
following infection and an increased risk of developing multiple sclerosis (5, 6).
EBV transmission occurs orally. Initial infection and replication of the virus most likely occurs
in epithelial cells and locally infiltrating B-cells, resulting in high levels of virus shedding in the
oropharynx (7–9). This lytic stage of viral replication is driven by up to 80 viral genes expressed
in a temporally regulated manner (7). At the same time, the virus drives a proliferation of B-
cells by activating its growth transforming programme. Here, viral gene expression comprises six
Epstein-Barr Nuclear Antigens (EBNAs: EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-
LP), two latent membrane proteins (LMPs: LMP1, LMP2) and the viral anti-apoptotic protein
BHRF1 (7, 10). This programme leads to the expansion of EBV-infected B cells in the oropharyngeal
lymphoid tissue and the appearance of infected B cells in the blood. In some infected B-cells the
virus downregulates its growth transforming program allowing the cells to enter the memory B-cell
pool with the virus persisting as a truly latent infection lacking viral gene expression (11). These
infected B-cells circulate between the blood and oropharyngeal lymphoid tissue and, in the latter,
may occasionally switch into lytic cycle, releasing infectious virus for transmission to new hosts and
for infection of new local B cells to maintain the viral reservoir (7).
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EBV has potent growth transforming activity, as
demonstrated in vitro by its ability to efficiently transform
B-cells into immortalized lymphoblastoid cells lines (LCLs) (12).
This property of the virus is used by laboratories worldwide
to simply and reliably generate permanently growing B cell
lines for research (13). The virus also has oncogenic potential,
as demonstrated by its association with several malignancies
that together total almost 200,000 cases of cancer each year
worldwide (14). Nevertheless, the large majority of people
infected by EBV do not suffer any long-term ill effects from
the virus. This is due to the anti-viral immune response which,
although unable to eliminate the virus, counters primary EBV
infection and then maintains subsequent lifelong control to
enable mutual co-existence of the virus and its host (8). Early
control of EBV infection is associated with expansion of innate
immune cells (primarily NK cells, described by Professor Munz
in this review series) and of CD8+ and CD4+ T-cells specific
for a broad range of EBV proteins expressed during the lytic
and latent stages of viral infection (8). Over time, these T-cell
responses decrease in magnitude but persist for the life time of
the host. Low frequencies of latently EBV-infected B-cells can,
nevertheless, be detected in the circulation (15) and infectious
virus is periodically produced in the oropharynx and secreted
in saliva (16, 17). Therefore, despite the exuberant primary
immune response that occurs immediately after infection,
and subsequent long-term immune surveillance, the virus
is able to successfully persist for life. This apparent détente
can, however, be broken if the balance between the virus
and its host’s immune response is disrupted. The clearest
demonstration of this is in immunosuppressed patients, where
loss of immune control of EBV can allow virus reactivation
and the accumulation of EBV-transformed B cells, leading to
post-transplant lymphoproliferative disease (PTLD) (18).
THE EBV-SPECIFIC T-CELL RESPONSE
DURING SYMPTOMATIC PRIMARY
INFECTION
Most work studying T-cell responses during primary infection
has investigated people identified as having been recently infected
with EBV through the overt symptoms of IM. The results of such
studies are valuable but need to be interpreted with two caveats.
First, in contrast to the vast majority of individuals who acquire
EBV asymptomatically in early childhood, IM represents an
atypical pathological state. Second, viral infection occurs several
weeks prior to symptoms developing and samples being taken
(19). On presentation, IM patients have unusually high numbers
of atypical lymphocytes in the blood, the magnitude of which can
resemble leukemia (20). Detailed analysis of blood from these
patients shows that the majority of the expanded lymphocytes
are EBV-specific T-cells (8). These largely comprise CD8+ T-cells
specific for the EBV lytic cycle proteins with a clearly defined
hierarchy. Most are specific for immediate early EBV lytic cycle
proteins, a smaller number are specific for early proteins with
few specific for late proteins (21–24). CD8+ T-cells specific for
latent cycle proteins are also expanded but to a smaller degree.
Of these, most are specific for the EBNA3A, 3B, and 3C proteins
with a lower frequency of LMP2-specific T-cells also present
(25, 26). Responses to the EBNA1 protein occur sporadically in
IM patients bearing particular HLA alleles, such as HLA-B∗3501;
that are uncommon in the general population. In people with
these alleles, however, the EBNA1-specific CD8 T-cell response
is strong (27). The phenotype of the CD8+ T-cell response has
been explored using HLA-class I tetramers. As might be expected
the EBV-specific CD8+ T cells are proliferating and highly
activated, expressing HLA-DR, CD38, and CD69 (28). They also
express the CD45RO isoform, lack expression of the lymphoid
homing markers CCR7 and CD62-L (26, 29), and are highly
susceptible to apoptosis, likely due to low expression of the anti-
apoptotic protein bcl-2 (30, 31). Given their extreme sensitivity
to apoptosis in vitro, with significant cell death occurring within
just a few hours, measurement of response size using directly
ex vivo methods such as HLA tetramer staining provide the
most accurate enumeration. Studies in IM patients using HLA
tetramers report that CD8+ T-cells specific for individual EBV
lytic and latent epitopes can account for 1–40 and 0.1–5% of total
CD8+ T cells, respectively (25, 26, 28).
Regarding the EBV-specific CD4 T-cell response, during IM
weak responses to lytic and latent cycle antigens are present
with the former observed more frequently (32, 33). This early
research utilized cytokine secretion assays to detect T-cells
reactive to recombinant antigens or lysates of EBV-infected cells.
As described above, the propensity of EBV-specific T-cells from
IM patients to undergo apoptosis in vitro may have limited
the sensitivity of this work. The recent development of HLA
class II tetramers has allowed this obstacle to be overcome and
the CD4+ T-cell response has now been accurately measured
(34). Ex vivo HLA tetramer staining and flow cytometry has
revealed that, although the overall size of the CD4+ T cell
compartment does not appear to be expanded (3), the early EBV-
specific CD4+ T-cell response is much stronger than previously
appreciated. Responses to individual epitopes can reach as high
as 1.5% of total CD4+ T-cells (34). Unlike the CD8+ T-
cell response, for CD4+ T-cells the latent antigen responses
numerically dominate the lytic. The exception is EBNA1, where
CD4+ T cell responses are undetectable or low in the blood
of patients with IM for several months before they develop
(34, 35). Interestingly, this delayed appearance is in line with the
previously documented but unexplained delay in EBNA1-specific
IgG antibodies (36, 37). Akin to the CD8+ T cell response, EBV-
specific CD4+ T cells express high levels of CD38 and CD45RO
and lack the lymphoid homing markers CCR7 and CD62L (34).
Considering the magnitude of the T-cell response to individual
antigens, CD4+T cells are smaller in number than CD8+T-cells.
However, the CD4+ T cell response is broader and targets more
epitopes (8, 38–40). The breadth of the CD4+ T-cell response
means that the total EBV-specific expansion is substantial and the
overall activation status and phenotype of the total CD4+ T cell
pool is altered within IM (34).
The functional profile of EBV-specific CD4+ T cells is
consistent with Th1-like cells: most express T-bet and the
predominant cytokine produced in ex vivo stimulation assays
is IFNg. Some cells also produce TNFα and/or IL-2, either in
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combination with IFNg or alone (41, 42). Early observations
of raised perforin expression within the total CD4+ T cells of
IM patients suggested that cytotoxic CD4+ T cells are present
during primary EBV infection (43). Recent ex vivo HLA class
II tetramer analysis has now shown that in fact the majority
of activated EBV-specific CD4+ T cells express both perforin
and granzyme B. Importantly, these cytotoxic proteins were not
detected in co-existing influenza A-specific memory CD4+ T
cells demonstrating that such expression was not due to non-
specific bystander activation (42). Testing with EBV peptides
has shown that some EBV-specific CD4+ T cells upregulate cell
surface CD107a indicating degranulation and release of perforin
and granzyme is possible (41). These observations strongly
suggest that EBV-specific CD4+ T cells can exert cytotoxic
function in vivo; if this is the case they could be highly effective
against MHC-II positive EBV infected B cells.
Over time the symptoms of IM resolve with a concomitant
decrease of both EBV DNA load and the frequency of EBV-
specific CD8+ and CD4+ T-cells in the peripheral blood to
values typical of life-long virus carriage (23, 34, 44, 45). All
specificities decrease in magnitude although the predominant
lytic antigen-specific CD8+ T-cell responses decline the most
(25, 26, 34). The phenotype of the T-cells also changes. Activation
marker expression decreases and anti-apoptotic proteins such
as bcl-2 are upregulated (46). Latent antigen-specific CD8+ T-
cells also begin to upregulate lymphoid homing markers allowing
them to begin entering the tonsil, followed later and to a lesser
extent by lytic antigen-specific CD8+ T cells (23).
THE EBV-SPECIFIC T CELL RESPONSE
DURING ASYMPTOMATIC PRIMARY
INFECTION
Although the above studies have informed our understanding
of primary infection, most EBV infections occur in the absence
of IM (2). Identifying newly-infected asymptomatic individuals
is extremely challenging but has been achieved by several
longitudinal studies that tracked EBV seronegative individuals
over time. Together these studies provide an insight into the
immunological events occurring in response to EBV infection
in the absence of any clinical manifestation of disease. Early
studies of newly infected infants showed no perturbations of
the lymphoid compartment or febrile illness (47, 48). Newly
infected African children had high levels of EBV DNA in the
blood but no change in the overall size of the CD8 compartment.
High frequencies of activated EBV-specific CD8+ T-cells could
nevertheless be detected (49). Similarly, newly infected young
adults also had high EBV DNA load in their blood but
lacked lymphocytosis and the size of their T-cell compartment
was unchanged (50). A recent prospective study of University
students in the United Kingdom identified several individuals
undergoing silent infection (51). Each had high EBV viral loads in
the blood, reminiscent of IM, but no marked disturbance of total
T cell or NK cell frequencies. Of three individuals with the highest
viral loads, two had concurrent expansions of EBV-specific
CD8+ T cells. In the third individual, EBV-specific T cells did
not appear in the blood for several months until the peripheral
viral load had decreased (51). Taken together, these studies
strongly suggest that in asymptomatic individuals EBV infection
elicits a virus-specific CD8+ T cell response. Although lower in
magnitude than that seen in IM, this response is nevertheless
sufficient to control the infection. The overall conclusion from
this body of work is that the characteristic symptoms of IM
result from the globally large expansions of highly-activated
EBV-specific T-cells, which are predominantly CD8+.
THE EBV-SPECIFIC T-CELL RESPONSE
DURING PERSISTENT INFECTION
EBV-specific T-cell responses are readily detected in the blood
of healthy EBV carriers and are present at similar frequencies
regardless of whether an individual experienced symptomatic or
asymptomatic primary infection (8). CD8+ T-cell responses to
lytic and latent cycle antigens are present, the former occurring
at higher frequency. Individual lytic epitope-specific responses
can account for up to 2% of the total CD8+ T-cell population.
The lytic antigen hierarchy seen in IM patients is broadly
maintained in memory: responses to immediate early antigens
dominate those to early antigens and responses to late-expressed
antigens are rare (22, 24). For latent antigen-specific responses,
CD8+ T-cells targeting the EBNA3A, 3B, and 3C proteins are
dominant. Fewer sub-dominant responses specific for EBNA1,
EBNA2, and LMP2 are present; responses against EBNA-LP
and LMP1 are rare (8). This general rule is, however, not
observed in individuals possessing particular HLA types. Thus,
individuals carrying HLA-B∗3801 possess strong responses to an
EBNA2 epitope and those carrying HLA-A∗0203 possess strong
responses to an epitope from EBNA-LP (30, 52). Phenotyping of
HLA-I class tetramer-stained cells shows that the EBV-specific
T-cell repertoire in persistently infected individuals contains
resting antigen-experienced T-cells that are neither activated nor
proliferating (30, 52). However, upon antigen challenge these
cells exhibit potent effector functions including cytotoxicity and
cytokine secretion (29, 52). Expression of lymphoid homing
markers, such as CCR7 and CD62L, are variable but are generally
expressed more frequently on T-cells specific for latent antigen
compared to lytic antigens (52). The phenotype, functional
profile and TCR clonotype composition of the virus-specific
CD8+ T-cells is stable over many years (53, 54).
Compared to the CD8+ T cell response, the EBV-specific
CD4+ T-cell response in healthy carriers is much smaller but
the greater diversity of epitopes targeted by these cells in IM is
maintained (34, 38–40, 55). Considering responses to individual
epitopes, the CD4+ T-cell response is often 10-fold lower than
the CD8+ T cell response to the same antigen (33, 34, 38, 39,
56). Across different antigens, latent antigen-specific responses
outnumber lytic antigen-specific responses in magnitude. Lytic
antigen-specific CD4+ T-cells are equally distributed against
the immediate early, early and late antigens (39, 40); the heavy
skewing exhibited by CD8+ T-cells is absent. HLA class II
tetramer analysis shows that EBV-specific memory CD4+ T cells
have the same phenotype regardless of whether they target latent
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or lytic antigens. They do not express activation markers and
are evenly distributed between the CCR7+ central memory and
CCR7- effector memory subsets (34). Compared to CD4+ T-cells
in IM patients, they no longer express perforin and granzyme,
and upon ex vivo stimulation their cytokine polyfunctionality
is increased with TNFa being the most predominant cytokine
produced (41, 42, 57).
LOCATION, LOCATION, LOCATION: THE
EMERGING IMPORTANCE OF RESIDENT
T-CELL MEMORY
Much of our understanding of EBV-specific T cell immunity
has come from studying circulating virus-specific T cells because
sampling blood lymphocytes is convenient and minimally
invasive. However, such analyses do not provide a complete
picture of overall immune control. Recent studies in mice have
highlighted the vital role of local immune responses, including
virus-specific tissue resident memory T-cells (Trm cells), in
providing long-term protective immunity against viral infection
(58). Trm cells reside at sites of infection, where they enable
rapid local immune responses against reactivation or secondary
infection. Studying immunity in human tissues naturally presents
a far greater challenge. Nevertheless, CD8+ and CD4+ Trm
cells have been detected in a range of lymphoid and non-
lymphoid tissues (59). These cells are transcriptionally distinct
from circulating memory T cell populations (60).
Investigation of local EBV-specific T cell responses within
tissues has been achieved by analysis of tonsils, which represent
one of the major oropharyngeal sites of EBV infection and
reactivation. In IM patients EBV loads in the tonsils are high
yet EBV-specific CD8+ and CD4+ T cells are markedly lower in
frequency at this site than in the blood of the same individual (23,
34, 42). Unlike lymph nodes, where T-cells may enter passively
via afferent lymph vessels, entry into tonsils is dependent on
transition across high endothelial venules (61). Expression of the
lymphoid homing markers required for this process, CCR7 and
CD62L, is highly downregulated on EBV-specific T cells in IM
patients (26, 28, 34). This likely explains why EBV infection in
the oropharynx is inefficiently targeted by virus-specific T cells
during IM. As the symptoms of IM resolve, latent antigen-specific
CD8+ T cells in the blood re-express CCR7 and CD62L and
this coincides with their increasing frequency in the tonsil. At
this time, some tonsillar latent antigen-specific CD8+ T cells
express high levels of the activation marker CD38, consistent
with encountering antigen at that site. In contrast, lytic antigen-
specific CD8+ T cells remain CCR7-negative in the blood for
several months after IM and their accumulation in the tonsils
is correspondingly delayed. This delay may explain why lytic
infection is not controlled in the throat of IM patients who
continue to shed virus in saliva for many months after primary
infection (23, 44).
In long-term EBV carriers the picture is reversed. Latent
and lytic antigen-specific CD8+ T cells are higher in frequency
in the tonsils than in the blood and the accumulated tonsillar
EBV-specific CD8+ T cells no longer express the activation
marker CD38. The degree of enrichment in the tonsils varies
for latent vs. lytic antigen specific T-cells, with the former
preferentially enriched compared to the latter (10-fold and 4-
fold enrichment in the tonsil respectively) (23). This variable
enrichment reflects the expression of CCR7 and CD62L on T-
cells in the blood (26, 28) but other factors are likely involved.
Thus, enrichment of EBV-specific CD8+ T-cells occurs only
in the tonsils (and presumably other oropharyngeal lymphoid
tissues) but not lymph nodes from other anatomical sites nor
bonemarrow (62, 63). The TCR repertoire of EBV-specific CD8+
T-cells within tonsils and blood of the same individual shows little
difference (31) suggesting that tonsillar T-cell enrichment is not
the result of selective recruitment or clonal expansion with the
tonsil site.
Most EBV-specific CD8+ T cells in the tonsils of long-
term EBV carriers express CD69 (64), one of the distinguishing
markers of Trm cells (60). CD69 is a C-type lectin that mediates T
cell retention in tissues and secondary lymphoid organs through
sequestration of sphingosine-1-phosphate receptor (S1PR), a
key molecule required for egress (65, 66). Although CD69 is
also transiently expressed upon T cell activation (67) there
is no concurrent raised expression of other cellular activation
markers, including CD38 and HLA-DR, suggesting that CD69
expression in this context reflects active T cell retention rather
than activation. In long-term EBV carriers, many tonsillar
EBV-specific CD8+ T cells also express CD103 (αEβ7), an
integrin that binds to E-cadherin and mediates retention
at epithelial sites (23, 64). In contrast, this protein is not
detected on the lower frequency EBV-specific CD8+ cells
present in the tonsils of IM patients (23). Importantly, the
CD103+ CD8+ subset of T cells from long-term EBV carrier
tonsils show greater sensitivity in vitro to stimulation with
cognate antigen (68). Elegant immunofluorescence microscopy
of human tonsils has revealed that CD69+CD103+CD8+T cells
preferentially localize at or near the tonsillar lymphoepithelial
barrier (64). Although analysis of antigen specific T cells was
not possible in this study, this observation suggests that EBV-
specific CD8+ T cells of this phenotype may be retained
in close proximity to the tonsillar epithelium, the region
of the tonsils where EBV-positive B cells are predominantly
found (69, 70).
BEYOND αβ: ACCUMULATING EVIDENCE
OF A ROLE FOR γδ T-CELLS
All of the research described above has studied the αβ subset of
T-cells and how these respond to EBV in primary and persistent
infection. These T-cells express T-cell receptors composed of a
heterodimeric α and β chain which enables them to recognize
peptide epitopes presented by HLA molecules (8). A second
subset of T-cells exists that express a different T-cell receptor
formed from a heterodimeric γ and δ chain. These γδ T-cells
can, in humans, be broadly divided into two groups based on
the type of δ chain they express. T-cells expressing the Vδ2 chain
are more abundant in the blood, where they comprise 90% of
the circulating γδ T-cell pool (71). Cells expressing the Vδ1 chain
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occur at low levels in the blood but comprise the bulk of γδT-cells
in tissues (72).
There is good evidence from mouse studies that γδ T-cells
are involved in protection from herpesviruses such as murine
cytomegalovirus (73, 74). A role for γδ T-cells in cancer is also
suggested both by studies in mouse cancer models (75) and in
humans by associations observed between intratumoural γδ T-
cell frequency and prognosis (76). Several lines of evidence now
show that γδ T-cells also play an important role in controlling
EBV infection and transformation.
γδ T-CELLS IN INFECTIOUS
MONONUCLEOSIS
Only a small number of studies have examined γδ T-cell during
IM. Two studies, each analyzing 10 IM patients and a number
of matched controls, showed an increased frequency of γδ T-
cells in the blood by flow cytometry, with up to a 4-fold
increase in absolute number (77, 78). The majority of γδ T-
cells in IM patients were positive for the cell surface activation
marker CD38 whereas this marker was absent from γδ T-
cells in healthy donors (77) A larger study detected increased
αβ and γδ TCR gene expression in the blood of IM patients
by transcriptional analysis. Based on a deeper analysis of the
transcriptome the authors suggest that both the Vδ1 and Vδ2
subsets are increased in IM (79). Because increases in RNA levels
may not necessarily reflect changes in cell frequency the authors
performed confirmatory flow cytometry analysis of a subset of
patients which demonstrated a 3.4-fold increase in γδ T-cell
frequency in IM (79). Note that the antibody used for this work
was unable to differentiate between the two γδ T-cell subsets so
the relative contribution each makes to the overall expansion of
γδ T-cells in IM requires further investigation.
The above observational studies cannot determine whether
the increases in γδ frequency that occur in IM are an indirect
result of bystander activation or represent direct recognition
of EBV infected cells. An experiment of nature suggests
the latter may be the case. An EBV-negative recipient of
a cord blood transplant, who acquired EBV 31 days after
transplantation, experienced prolonged high-level EBV viremia
yet did not develop any clinical manifestations of EBV-
associated disease. This patient lacked detectable EBV-specific
αβ T-cells by HLA class I tetramer staining and interferon-
gamma ELISpot assays (80) but had large expansions of γδ
T-cells that reached almost 50% of total T-cells. These cells
were mostly Vδ1 T-cells but a smaller number of Vδ2 T-
cells were also present. The Vδ1 T-cells were predominantly
CD45RA- CD27+ central memory cells and, based on their
expression of CD57, the authors concluded they were activated.
Interestingly, the γδ T-cells were able to degranulate when
exposed to an EBV+ve cell line in vitro suggesting direct
recognition of EBV+ve cells was possible. In a separate study,
an abundant Vδ1 T-cell clone isolated from a recipient of an
allogeneic stem cell transplant killed autologous and allogeneic
LCLs but not the EBV-ve Raji Burkitt Lymphoma (BL) cell
line (81).
γδ T-CELLS AND EBV-ASSOCIATED
NEOPLASMS
EBV is associated with malignancies arising in different cell
backgrounds. Examples include BL, a tumor of B cells that occurs
predominantly in Sub Saharan Africa, and nasopharyngeal
carcinoma (NPC) an epithelial carcinoma that occurs at high
incidence throughout South East Asia. γδ T-cells are altered in
patients with these EBV+ve malignancies. Two papers studying
patients with NPC both report that while the frequency of γδ T-
cells in patients is unaltered their functional capacity is impaired.
Following in vitro culture, peripheral blood mononuclear cells
(PBMCs) from NPC patients yielded smaller numbers of γδ
cells compared to control donors and were unable to kill an
NPC cell line (82). When tested in cytotoxicity assays, γδ T-
cells from patients lacked the ability to kill CNE-2, a tumor
cell line established from an NPC patient (82). Interestingly,
this deficit in NPC cell killing was found only in patients
with active NPC since γδ T-cells from successfully-treated NPC
patients exhibited the same level of cytotoxicity against CNE2
as those from control donors. Similarly, another research group
found that Vγ9Vδ2 T-cells from NPC patients, but not healthy
donors, were unable to lyse the NPC cell line HK1 or the
control cell line K562 when tested directly ex vivo (83). In this
study Vγ9Vδ2 T-cells from NPC patients also produced less
interferon-gamma and TNFα than cells from control donors
when exposed to HMBPP, a phosphoantigen that is a potent
stimulator of Vγ9Vδ2 T-cell activity. Flow cytometry analysis
showed that Vγ9Vδ2 T-cells in NPC patients were more highly
differentiated, with a smaller proportion of central memory and
higher proportion of terminally differentiated TEMRA cells. A
study in BL patients in Ghana reports that patients have lower
Vγ9Vδ2 T-cell frequency than healthy donors (84). Whether the
functional capacity of Vγ9Vδ2 T-cell in BL patients is impaired
is unknown.
In several of the above papers, γδ T-cells were reported
to be capable of recognizing EBV+ LCLs (80–82), the NPC
cell line HK1 (83) or the NPC cell line CNE2 (82); note
that experiments using CNE2 need cautious interpretation
as it has been shown to be contaminated with HeLa (85).
These observations raise the question of which cellular targets
render EBV+ve cells visible to γδ T-cells. In this regard
it is important to point out that γδ T-cell recognition of
target cells is complex and can involve the T-cell receptor
and/or ligands for natural killer receptors they express, such as
NKG2D (86, 87).
γδ T-CELL RECOGNITION OF EBV+VE
CELLS
The BL line Daudi (88) is a reliable stimulator of Vγ9Vδ2
T-cells and has been used for many years for this purpose
(89–99). These studies also often included other BL cell
lines which in contrast showed lower or indeed no γδ T-
cell stimulatory activity. Indeed, the BL line Raji, as well as
LCLs, were often used as a negative controls in such work.
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It is now known that Daudi overproduces endogenous non-
peptidic phosphorylated metabolites due to upregulation of the
mevalonate pathway (96) resulting in intracellular accumulation
of IPP, a host phosphoantigen counterpart of HMBPP (100).
Vγ9Vδ2 T-cell phosphoantigen sensing is dependent on: (i)
target cell exposure to/accumulation of HMBPP and IPP
and (ii) target cell expression of BTN3A1, which binds
phosphoantigens via its intracellular B30.2 domain (101). It
is currently unclear why most BL cell lines are unable to
generate Vγ9Vδ2 T-cell lines when co-cultured with PBMCs,
however, this potentially could reflect deficient expression of
BTN3A1 or insufficient IPP production. These possibilities
require further investigation.
Interestingly, being able to generate Vγ9Vδ2 T-cell lines
and being able to be recognized by those same cells appear
to be distinct properties. Thus, Daudi-stimulated Vγ9Vδ2
T-cells are able to recognize and kill multiple BL lines
that themselves lack stimulatory activity for Vγ9Vδ2 T-
cells (94). This difference between the ability to generate
Vγ9Vδ2 T-cells and being sensitive to γδ T-cell recognition
could be due to: (i) activated Vγ9Vδ2 T-cells possessing
increased sensitivity to a lower level of phosphoantigens and/or
BTN3A1 (ii) Daudi stimulated Vγ9Vδ2 T-cells being able
to utilize alternative target recognition mechanisms that are
independent of phosphoantigens. For example, Vγ9Vδ2 T-
cells expressing NKg2D can recognize target cells expressing
ULBP4, a protein upregulated upon EBV infection of B-
cells (102).
Additional complexity is suggested by a recent report of
a fundamental population-level difference in the response to
BL lines (99). After co-culturing PBMCs from 24 donors with
EBV+ve Akata BL cells for 10 days in vitro, Djaoud and
colleagues found that 13 co-cultures had large expansions of
Vγ9Vδ2 T-cells and NK cells. In contrast, the other 11 co-
cultures had a large expansion of NK cells but only very small
increases in Vγ9Vδ2 T-cells. Vγ9Vδ2 T-cell expansion was
sensitive to an anti-BTN3A1 blocking antibody or mevastatin,
an inhibitor of the mevalonate pathway that generates the
intracellular phosphoantigens recognized by Vg9Vd2 T-cells.
Interestingly, the authors reported that Vγ9Vδ2 T-cell expansion
did not occur when the EBV-ve derivative of the Akata BL
cell line was used instead. The authors extended their work
to include a larger range of EBV+ve stimulator cells. These
experiments used the EBV+ve Akata BL cell line as well as
the EBV+ve BL cell lines Daudi and Kem-I (all three are type
I BL lines expressing EBNA1), Sal (a Wp-restricted BL line
that expresses EBNA1 but also EBNAs 3A, 3B, and 3C along
with a truncated form of EBNA-LP) and Raji and Jijoye (the
EBV+ve variants of these two lines express all EBV latent cycle
proteins). Only the type I BL cells (Akata, Daudi, and Kem-
I) stimulated Vγ9Vδ2 T-cell expansion (99). This result led the
authors to conclude that Vγ9Vδ2 T-cell expansion was a property
of type-I BL cells only. Independent confirmation of these results
and testing of a larger range of B-cell lines is now needed to
determine if Vγ9Vδ2 T-cell recognition is indeed limited solely
to type I BL lines and to reveal the underpinning biological
mechanisms responsible.
γδ T-CELLS IN MOUSE MODELS OF EBV
Further support for a role of Vγ9Vδ2 T-cells in the control
of EBV comes from studies in mice. Growth of CNE2 cells
injected subcutaneously into nude mice was slowed following
intravenous administration of Vγ9Vδ2 T-cells (103). More
advanced mouse models now exist including mice reconstituted
with human immune components which, arguably, are better
models in which to study EBV immunology (104). Work using
an early form of this model, CB.17scid/scid mice [severe combined
immunodeficient (SCID) mice] injected intraperitoneally with
peripheral blood lymphocytes, showed increases in γδ T-cells
following administration of irradiated Daudi cells. These mice
were protected against subsequent challenge with non-irradiated
Daudi cells but not non-irradiated Raji BL cells which developed
into disseminated lymphoma (105).
Control of EBV-driven lymphoproliferations and lymphomas
has been demonstrated by two studies that used more
advanced mouse models. The first used EBV-transformed
LCLs as targets of Vγ9Vδ2T-cells (106). In preliminary in
vitro work, phosphoantigen-specific Vγ9Vδ2T-cells were
unable to recognize LCLs, a result consistent with previous
publications. However, when the same Vγ9Vδ2 T-cells
were positively selected using magnetic beads they then
recognized and killed LCL cells. The authors suggested
that binding of the anti-γδ antibody-loaded beads to the
Vγ9Vδ2 T-cell receptor may have activated the cells thereby
allowing them to recognize LCLs. Cytotoxicity of the T-cells
was inhibited by concanamycin A, a widely-used inhibitor
of perforin-mediated cytotoxicity. A somewhat surprising
observation, however, was that purified bcl-2 protein also
inhibited cytotoxicity: how an extracellular protein was able to
enter the LCLs to inhibit intracellular granzyme activity was
not discussed.
Initial in vivo experiments, using immunodeficient Rag2−/−
γc−/− mice injected with LCLs, then showed that adoptive
transfer of magnetically enriched Vγ9Vδ2 T-cells could prevent
LCL-induced lymphoproliferative disease and eliminated
established LCL tumors (106). Extending the work to Rag2−/−
γc−/− mice carrying human immune components (established
by injection of PBMC) showed these mice carried human
Vγ9Vδ2 T–cells and that LCL tumors were rejected after the
mice were treated with pamidronate, a drug that stimulates
Vγ9Vδ2 T-cells (106). The reasons why Vγ9Vδ2 T-cells in
these mice did not require activation via bead selection in order
to recognize and kill LCLs was not explored. Pamidronate-
induced tumor rejection was, however, clearly Vγ9Vδ2 T-cell
dependent. These results raise the interesting possibility that
patients with PTLD could one day be treated using small
molecular agents to activate their own Vγ9Vδ2 T-cells. Several
ways to achieve this in the clinic can be envisaged (107)
including using zoledronate, a drug licensed to treat bone
diseases but which also exhibits potent Vγ9Vδ2 stimulatory
activity (96).
Work by another group also suggests that Vγ9Vδ2 T-cells may
be able to eliminate LCLs in vivo without requiring activation
via bead selection. Here the model used was the Rag2−/−
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γc−/− system but now using human cord blood to reconstituted
the mice with human immune components (108). Spontaneous
EBV-driven lymphoproliferations could be induced in the mice
by infecting the cord blood with EBV immediately prior to
injection. Adoptive transfer of Vγ9Vδ2 T-cells (generated in vitro
but without magnetic bead selection) soon after reconstitution
prevented lymphoma development. Delaying adoptive transfer of
Vγ9Vδ2 T-cells until tumors were evident retarded tumor growth
but did not eliminate them.
Finally, although far fewer studies have investigated Vδ1 T-
cell recognition of EBV targets, the available data clearly shows
marked differences exists between the Vδ1 andVδ2 T-cell subsets.
Thus, Vδ1 T-cells are not stimulated by Daudi BL cells but
are instead stimulated by LCLs (109–111). Regarding other BL
lines, in one study, Daudi, Raji, Ramos, BL41, and BL57 did
not stimulate Vδ1 T-cells (111) whereas Raji was reported to
be stimulatory by another (109). These disparate results may
reflect the fact that Vδ1 cells employ a range of target recognition
mechanisms (72).
Collectively the above results clearly show that both γδ T-
cell subsets warrant far greater attention then has been the case
in the past. Which subset will prove to be more important in
controlling EBV remains to be determined. Indeed, the critical
effector subset may vary as individuals progress from primary
infection into the long term carrier state and, for a minority,
develop an EBV+ cancer.
A ROLE FOR NATURAL KILLER T (NKT)
CELLS IN CONTROLLING EBV?
A limited number of studies have examined the contribution
of NKT cells to EBV immunity. NKT cells are a conserved
population of innate-like T cells that express the semi-invariant
Vα24-Jα18/Vβ11 T cell receptor. Unlike conventional αβ T cells,
NKT cells recognize glycolipid antigens presented by the non-
polymorphic MHC class I-like molecule, CD1d (112). Only one
study has assessed the frequency of NKT cells in the blood
during EBV infection (113). Using flow cytometry, no expansion
of CD3+CD56+CD244+ NKT cells was detected in 11 acute
IM patients compared to age-matched healthy carriers. A larger
study to assess the frequency and function of Vα24-Jα18/Vβ11+
NKT cells is required to confirm this observation. Nevertheless,
a possible role for NKT cells in immune control of EBV is
supported by the following lines of evidence. (i) NKT cells
are significantly lower in frequency in the blood of EBV+ HL
and NPC patients than in healthy carriers (114). Furthermore,
NKT cells derived from these patients were less functional upon
stimulation with the synthetic glycolipid α-GalCer in vitro. (ii)
In patients with primary immunodeficiency, individuals with
genetic mutations that affect the NKT cell lineage are predisposed
to develop EBV-associated disease (reviewed by Professor Munz
in this series). Importantly, however, such mutations rarely affect
NKT cells in isolation and most patients have coexisting defects
in NK and/or T cell development and/or function. Therefore,
deciphering the precise contribution of NKT cell deficiency to
the lack of overall immune control of EBV in these patients
is extremely challenging (115). (iii) The presence of NKT cells
reduces EBV transformation of B cells in vitro. Upon infection
of PBMCs with EBV, prior depletion of NKT cells led to both
increased numbers of EBV-infected B cells and raised overall
viral titers in the cultures (116). Interestingly CD1d expression
was lost from the B cell surface during transformation, and NKT
cells were subsequently unable to recognize fully transformed
LCL cell lines. The authors therefore suggest that NKT cells
may be important for early immune recognition of newly EBV-
infected B cells, and exert their function prior to EBV-driven
downregulation of CD1d (116). Note that similar downregulation
of CD1d has been reported in KSHV and HSV-1 infected cells
(117, 118), suggesting that evasion of NKT cell surveillance may
be a common strategy of herpesviruses.
CONCLUSIONS
Research on EBV continues to reveal new tricks employed
by the human T cell immune system to control infection
with this ancient virus. Novel techniques have enabled deeper
understanding of the targets, function and evolution of the CD8+
and CD4+ T cell responses, and the potential contributions
of previously neglected unconventional T cell subsets are
increasingly coming to light. Although it is challenging to obtain
tissue samples from people, studying EBV-specific immunity at
the site of infection is vital if we are to fully understand the
interplay between the virus and its host. With this in mind,
we note the current dearth of information on intra-tumoural
EBV-specific immunity and highlight this area as a priority for
future research.
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